Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxicotherapy: present status and future trends.

J M Scherrmann1, N Terrien, M Urtizberea

  • 1Inserm U.26, Hôpital Fernand Widal, Paris, France.

Journal of Toxicology. Clinical Toxicology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gradual Acidification at the Oral Biofilm-Implant Material Interface.

Journal of dental research·2024
Same author

Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy.

The AAPS journal·2020
Same author

[Children and adolescents' anxiety disorders].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2016
Same author

[Pathological nighttime fears in children: Clinical specificities and effective therapeutics].

L'Encephale·2014
Same author

Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Antimicrobial agents and chemotherapy·2013
Same author

ABC drug transporter and nuclear receptor expression in human cytotrophoblasts: influence of spontaneous syncytialization and induction by glucocorticoids.

Placenta·2012
Same journal

Ingestion of high-dose buprenorphine by a 4 year-old child.

Journal of toxicology. Clinical toxicology·2005
Same journal

A reassessment of topical organic phosphorus insecticide exposures and permanent paralysis.

Journal of toxicology. Clinical toxicology·2005
Same journal

Methamphetamine toxicity secondary to intravaginal body stuffing.

Journal of toxicology. Clinical toxicology·2005
Same journal

Duodenal perforation after ibuprofen overdose.

Journal of toxicology. Clinical toxicology·2005
Same journal

Delayed dystonia following pimozide overdose in a child.

Journal of toxicology. Clinical toxicology·2005
Same journal

Pattern of acute poisonings in Mashhad, Iran 1993-2000.

Journal of toxicology. Clinical toxicology·2005
See all related articles

Immunotoxicotherapy (ITT) uses antibody fragments to neutralize toxins like snake venom. Optimizing dosage and infusion strategies, alongside advancements in antibody technology, can improve ITT effectiveness and safety.

Area of Science:

  • Immunology
  • Toxicology
  • Pharmacology

Background:

  • Immunotoxicotherapy (ITT) is an established treatment for specific poisonings, but requires optimization.
  • Current ITT protocols often rely on empirical testing, indicating a need for improved methodologies.
  • The efficacy of ITT depends on the pharmacokinetics of antibody binding sites (ABS) and their interaction with toxins.

Purpose of the Study:

  • To review and suggest improvements for Immunotoxicotherapy (ITT).
  • To analyze the pharmacokinetic and toxicokinetic principles governing ITT.
  • To explore the potential of advanced immunologic tools in enhancing ITT.

Main Methods:

  • Review of existing literature on Immunotoxicotherapy (ITT) mechanisms.
  • Analysis of pharmacokinetic and toxicokinetic data related to antibody binding sites (ABS).

Related Experiment Videos

  • Evaluation of clinical data on the efficacy and limitations of different ABS, such as Fab fragments.

    • Main Results:

    • The Fab fragment is commonly used in ITT due to favorable diffusion and renal excretion.
    • Standard stoichiometric calculations are insufficient for determining optimal ABS dosage.
    • Clinical observations suggest that some Fab fragments are eliminated without toxin neutralization, necessitating dosage adjustments.

    Conclusions:

    • Optimizing the balance between dosage and infusion duration is crucial for improving ITT outcomes.
    • Advances in immunologic techniques, including monoclonal and chimeric antibodies, offer solutions to immunogenicity and adverse reactions.
    • Further research into ITT mechanisms and antibody engineering can enhance treatment efficacy and patient safety.